Form 4: Mineralys Therapeutics CEO Jon Congleton Sells Shares Under 10b5-1 Trading Plan

Mineralys Therapeutics CEO Jon Congleton sold 15,319 shares of common stock at a weighted-average price of $12.1942 on April 11, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 11, 2025, Jon Congleton, the CEO of Mineralys Therapeutics, sold 15,319 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on January 30, 2024.
• The shares were sold at a weighted-average price of $12.1942, with individual prices ranging from $12.0200 to $12.4087.
• Following the transaction, Congleton directly owns 862,289 shares of Mineralys Therapeutics.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a negative outlook on the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on non-public information. The market typically views these sales in the context of the overall financial health and prospects of the company.

Stakeholder Impact

• The sale of shares by the CEO could potentially create short-term negative sentiment among shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Mineralys Therapeutics, Jon Congleton, MLYS, Form 4, SEC, Share Sale, Rule 10b5-1, CEO, Insider Trading